Figure 4.

T_MH60-mediated GVL requires that the target leukemia expresses H60. B6.H60 mice were irradiated and reconstituted with T cell–depleted C3H.SW BM, B6.H60 or B6 (H60⁻) mBC-CML cells, with no T cells, or with CD8⁺ T_M from DEC-H60–vaccinated or unmanipulated C3H.SW donors or CD8⁺ T_N from unmanipulated C3H.SW mice. (A) Survival. All deaths were from leukemia. P < .0001 comparing T_MH60 recipients of B6.H60 with recipients of B6 mBC-CML cells. (B) Numbers of NGFR⁺EGFP⁺ cells in peripheral blood at day 14. P < .0001 comparing T_MH60 recipients of B6.H60 versus B6 H60⁻ mBC-CML cells. P = .5 comparing B6 mBC-CML recipients of T_MH60 or T_M. Recipients of T_MH60 mounted similar anti-H60 responses whether they received B6.H60 or B6 mBC-CML cells. (C) Representative flow cytometry. (D) Percentage of peripheral blood CD8⁺ cells that are Tet^H60+ in T_MH60 recipients at multiple time points.